The purpose of the study was to develop a transdermal tolterodine tartrate (TT) patch and to analyse its effi cacy for overactive bladder (OAB) treatment. Patches were prepared using various polymers and plasticizers via the solvent casting method. The patches were characterized for tensile strength, thickness, moisture content, modulus of elasticity and water absorption capacity. Diff erential scanning calorimetry and Fourier transform infrared analyses were also performed. To determine patch eff ectiveness, in vitro release, permeation and animal studies were performed. The patches showed satisfactory percentage of release, up to 89.9 %, and their mechanical properties included thickness (0.10-0.15 mm), tensile strength (4.62-9.98 MPa) and modulus of elasticity (20-29 MPa). There were no signifi cant interactions between TT and other excipients. Animal studies indicated that the TT patch reduced the incidence of side eff ects; however, studies of longer duration are required to determine the eff ectiveness in treating OAB.
The International Continence Society (ICS) defi ned overactive bladder (OAB) as "a collection of symptoms suggestive of lower urinary tract dysfunction such as urgency, with or without urge incontinence, normally accompanied with frequency and nocturia" (1) . The National Overactive Bladder Evaluation (NOBLE) study reported that OAB aff ects approximately 16 % of the population (2) and aff ects the quality of life of patients. Pharmacological anti-muscarinic molecules like trospium, oxybutynin and tolterodine tartrate (TT) are used in the treatment of this chronic condition (3) . However, oral administration exposes patients to side eff ects such as headache, constipation and dry mouth (4) . To minimize these side eff ects and to improve compliance, transdermal delivery is a promising alternate route (5) . Th is non-selective, competitive anti-muscarinic agent, TT, is recommended as a fi rst-line pharmacological treatment for OAB (6) . Upon administration, TT is metabolized by the liver (Cytochrome P450 2D6) to pharmacologically active 5-hydroxy-methyl derivative (7, 8) . The drug has in vivo functional selectivity for muscarinic receptors in the bladder over the salivary glands and hence it is suitable for the treatment of OAB (9, 10) . Transdermal delivery allows superior control of systemic drug concentration, by-passes fi rst pass metabolism, minimizes gastrointestinal side eff ects, allows immediate termination of administration in case of toxicity and greatly improves patient compliance (11) (12) (13) . Zhao reported that the fl ux of TT solution was not aff ected by addition of O-acylmenthol derived chemical enhancers but skin reservoir eff ects of enhancer-containing groups showed promising results compared to the control group (14) . Choi reported that free base TT penetrated hairless mouse skin about 10 times more eff ectively compared to other lipophilic salt forms (15) . Elshafeey et al. developed controlled release of the drug into the systemic circulation with the use of TT microemulsion, which was advantageous in prevention of nocturnal enuresis with improvement in patient compliance (16) . Similar studies of both oxybutynin and TT proniosomal gel were reported by our group to be suitable for transdermal route, which reduced the dry mouth eff ect compared to the oral route in our earlier studies (17, 18) . The drug had not been explored for transdermal delivery as a patch and this is the fi rst study that analyses the effi cacy of this formulation. The main aim of this research is to formulate a TT transdermal matrix patch possessing desirable physicochemical, release and permeation characteristics with reduced side eff ects as well as increased effi cacy for OAB.
EXPERIMENTAL

Materials
TT was a gift from Aurobindo Pharmaceuticals (India). Eudragit E 100, RS100, RL100, RSPO and RLPO were gift s from Evonik Röhm GmbH, Germany. EUDRAGIT ® polymers are copolymers derived from esters of acrylic and methacrylic acid whose physicochemical properties are determined by functional groups. In these studies, Eudragit E 100 is a cationic polymer with dimethylaminoethyl methacrylate as a functional group. Other Eudragit grades such as RS100, RL100, RSPO and RLPO are ethyl acrylate, methyl methacrylate copolymers with trimethyl-ammonioethylmethacrylate as diff erent ratios of the functional group. Polyvinyl pyrrolidone (Kollidon ® 30) was procured from the BASF Chemical Company, Germany. Dibutyl phthalate (DBP) was purchased from Qualigens Fine Chemicals, India. Triethyl citrate (TEC) was purchased from Merck Chemicals, Germany. Dibutyl Sebacate (DBS) was purchased from Sigma-Aldrich Chemie GmbH, Germany. All other chemicals used in the study were of analytical grade and were used as received.
Preparation of patches
The polymeric matrix formulation was prepared by dissolving diff erent grades ( E 100, RSPO and RLPO) of Eudragit polymers (200-400-600 mg) in chloroform, then 100 mg PVP was added under uniform stirring for 15-20 min. The patches were formed using the solvent casting method. To the above solution, one of the plasticizers (DBS/DBP/TEC) at either 10 or 15 % of total polymer mass and 8 mg of TT were added at room temperature under uniform slow stirring. The resulting solution was poured into casts that had an aluminium foil backing layer. It was drie d for 24-48 h at room temperature (19) . Table I con-tains details of the various formulation combinations. All formulations with the codes starting with A (A1, A2, A3) were designated as series A. All other series were similarly categorised into series B to F.
CHARACTERISATION OF TRANSDERMAL PATCHES
Patch thickness and tensile strength
A digital micrometer (Mitutoyo, Japan) was used for determining patch thickness (Table I) . Tensile strength was measured with a load of 50 kN at 5 mm/min extension speed using an Instron 4204, UK tensilometer. The test was performed according to the D 882 -75D method of the American Society for Testing Materials (ASTM) for 6 samples of each formulation patch. Temperature of 25 ± 2 °C and humidity of 56 ± 2 % were maintained throughout the test (19) . Equation (1) was used for tensile strength calculation.
where τ is tensile strength; L max is maximum load and A i is the initial cross-sectional area of the sample.
Modulus of elasticity determination
The modulus of elasticity refl ects the stiff ness or elasticity of transdermal patches. This indicates the resistance to distortion of the fi lms and was calculated by plott ing the stress strain curve using an Instron 4204, UK tensilometer. The modulus of elasticity is represented as the ratio of applied stress over strain in the region of elastic deformation and was determined using the following formula (2):
Moisture content
Matrix patches were independently weighed and preserved in a desiccator for a day at 40 °C. They were consecutively reweighed until a constant mass was established. The initial and constant fi nal patch mass diff erence was noted to calculate the moisture content percentage. Six readings were recorded and the average was calculated as described by Rajabalaya et al. (19) .
Water absorption
Water absorption capacity was determined by weighing the dry patches initially. They were then kept at two diff erent relative humidities for 24 hours at room temperature. Saturated sodium chloride solution and saturated ammonium hydrogen phosphate solution had yields of 75 and 93 % humidity, respectively. Patch mass was recorded periodically until it was constant. Average of six readings was recorded (Table I) (19) . 
Fourier Transform Infrared (FTIR) studies
Tolterodine tartrate, PVP, E 100 and their combination are depicted in Fig. 1a , while TT, RLPO, RSPO, PVP, TT and their combination are represented in Fig. 1b . Each component was mixed individually with KBr (IR grade) in the 100:1 ratio and pressurized using a hydraulic press to obtain pellets. These were scanned using an FTIR spectrophotometer in the range of 4000-400 cm -1 (FT-IR 8400S, Shimadzu, Japan).
In vitro release studies
Franz (vertical) Diff usion Cells (PermeGear, USA) were used for in vitro studies. A 1.7 cm 2 diameter matrix patch was placed carefully, with the backing membrane facing the atmosphere, on the receptor compartment that contained phosphate buff ered saline (PBS) at pH 7.4. The assembly was maintained at a uniform temperature of 32 ± 0.5 °C with uniform stirring speed of 50 rpm. Diff usion of the drug from the matrix patch was ensured by placing the drug side in contact with PBS in the receptor compartment. Every hour, 1 mL of the receptor sample was withdrawn and the same volume of buff er solution was replaced. The sample was measured using reverse-phase HPLC (1200 HPLC series; Agilent Technologies, Santa Clara, CA, USA) with a C-18 analytical column (5 μm, 4.6 × 150 mm; Phenomenex, Torrance, CA, USA). The sample was measured in UV at a 281 nm wavelength with 35:65, V/V of mobile phase (20 mM pH 3.0 acetate buff er/methanol) at an elution rate of 1 mL min -1 . The retention time was 5.5 min (15) .
Release kinetics data treatment
Various kinetic models, zero order, fi rst order Higuchi and Korsmeyer-Peppas were applied to the in vitro release data. These models serve to predict the release mechanism and kinetics of the drug from the transdermal matrix patch (Table II) .
In vitro permeation studies
Sprague Da wley rats (n = 6) were used in the study. Each rat was sacrifi ced as per the cervical dislocation method protocol. A section of the freshly excised abdominal rat skin treated in isotonic solution was bound intimately with a transdermal patch to the donor compartment without any air gap between the drug side of the patch and the stratum corneum side of the skin. The dermal side of the skin just touched the receptor liquid surface horizontally to allow drug permeation. The receptor compartment temperature, volume of sample collection and method of analysis were similar to the in vitro release study (17, 20) . The Internat ional Medical University (IMU) Research Ethics Committ ee (B0109_ Res182012) approved the procedures and animal care for the experiments undertaken in this project including pharmacological experiments. Percentage of permeation and permeation rate were calculated and are given in Table III. In vivo animal studies
Acetic aci d (ACA)-induced bladder hyperactivity
Male Sprague Dawley (SD) rats, initial mass 350-450 g, were used in the experiment. Rats were housed in the Animal Holding Facility (AHF) of the International Medical Uni-versity (IMU). They were housed in plastic cages, 3 rats per cage. The environment was maintained at ambient temperature with a 12 h light/12 h dark cycle. All rats were allowed free access to normal commercial rat feed pellets (Gold Coin Feedmills, Malaysia Sdn. Bhd) and reverse osmosis (RO) water. Rats were acclimatized for one week prior to experimental protocols. All the experimental procedures were performed in accordance with the guidelines issued by the International Medical University Joint Committ ee (IMU-JC) for Ethics.
Bladder infl ammation caused by the administered ACA solution (0.75 %) was evaluated histopathologically. A urinary catheter was used to administer the solution to unconscious rats. This model produces micturition due to the acute infl ammation caused in the urinary bladder by ACA (21) .
Measurement of salivary secretion
The experiment was conducted on diethyl ether anesthetized rats (21) . Cott on balls (3-5) were kept for 10 mins for saliva absorption; they were immediately weighed to avoid moisture loss. Both oral and patch treatments were given at 0 hour along with the pilocarpine injection. The amount of saliva collected in the cott on balls was measured at 2, 4, 12 and 24 h (17, 21).
Histological studies
Aft er the treatment period, each rat was anaesthetized and sacrifi ced as per protocol. The bladder was reached aft er dissecting the abdomen wall and exposing the peritoneum space. The bladder dome was dissected down to the level of ureteral insertion. The excision was done as a total cystectomy procedure involving ligating at the level of pelviureteric junction above and urethra below. This ensured that all 3 layers, urothelium, lamina propria and muscle layers were intact for the study. Bladders were fi xed in 10 % buff ered formalin overnight, processed, embedded in paraffi n, and cut into 5-μm slices. All staining was done on at least two diff erent areas of the bladder. These were then observed under a light microscope aft er hematoxylin and eosin staining (17) .
Statistical analyses
SPSS v18.0 (IBM Corp., USA) statistical soft ware was used for data analysis. Paired ttest and analysis of variance were both performed. p < 0.05 was considered signifi cant. Values are expressed as mean ± standard deviation.
RESULTS AND DISCUSSION
Diff erent grades of Eudragit polymers, PVP, diff erent categories of plasticizers, such as dibutyl sebacate (DBS), dibutyl phthalate (DBP) and triethyl citrate (TEC), used for the preparation of patches are presented in Table I . Mechanical properties of the matrix patch such as modulus of elasticity, tensile strength and thickness are also given in Table I .
Thickness and tensile strength
TEC is the most hygroscopic plasticizer and is followed by DBP and DBS; therefore, patches containing TEC (A3) had the highest thickness amongst series A, with E 100 fol-lowed by DBP and DBS containing patches (22) . Correspondingly, B3 and C3 had the highest thickness in their respective series. Likewise, similar observations were made with other Eudragit polymer grades (RSPO/RLPO) of D and E series patches. A tensile strength of 4 MPa and above is desirable for transdermal patches according to the American Society for Testing and Materials (ASTM) guidelines (23) . The data revea led that the average tensile strength of all the patches was in the range of 4.09 to 9.98 MPa, indicating good tensile strength. This can be illustrated with E3 having 4.09 MPa, which is the least in series E (22) . DBS patches (Ex: A1 -9.98 MPa) always maintained the highest tensile strength among their respective series compared to those of the other two plasticizers, while patches with DBP exhibited a higher modulus of elasticity (22.73 to 29.48 MPa) than the other two plasticizers.
Patch thickness increased in the formulations containing hydrophilic polymers such as PVP, RLPO and Eudragit RL100, as evidenced in Table I . Patch thickness in Eudragit E 100 series is the lowest compared to other series patches containing an additional PVP (B and C series). In contrast, the results of tensile strength of matrix patches decreased with an increase in the amount of PVP in the patches. Increase in the percentage of plasticizer from 10 to 15 % r educed the tensile strength of patches, as observed in the C and F series. The hygroscopi c nature of PVP may have increased the matrix patch bulkiness in the B and C series, as witnessed by lesser patch thickness with 100 mg PVP compared to patches with 200 mg (24) . Similarly, the hygroscopic nature of the plasticizer was also responsible for higher thickness of the patches.
The tensile strength data supports the possibility of polymer-polymer bond strength decrease due to the disruption in continuity of polymer chain molecules (19) . The molecular weight of the plasticizer also aff ects the tensile strength of matrix patches (25) . The descendi ng order of plasticizer molecular weight used in this study is DBS>DBP>TEC. Low molecular weight plasticizers increase the plasticizing eff ect by increasing the space between the polymeric chains, thus reducing the tensile strength. Optimal tensile strength for the patch is necessary to keep the patch on the skin and withstand the movements of daily life. The prepared patches had the necessary tensile strength for everyday wear.
Moisture content and water absorption studies
Moisture content of patches with hydrophilic excipients (PVP and RLPO) was higher compared to that of hydrophobic nature polymeric patches ( E 100 and RSPO). Matrix patches with TEC (A3, B3, C3, D3, E3 and F3) exhibited increased water absorption capacity in both 75 and 93 % RH due to the hygroscopic nature of TEC. Higher amount of PVP (200 mg) accounts for the higher moisture content of the PVP containing patches, namely, F3 with 0.881 % (m/m). Both B and C series had lower and higher PVP content, respectively, and exhibited proportionate water absorption capacities with B having lower capacity. A similar patt ern was displayed by the E and F series (22) . Hydrophilic plasticizer TEC was also responsible for higher moisture uptake and water absorption capacity. Moisture content and water absorption capacities of the E 100 patches were dependent on the concentration of plasticizer and PVP used in the study (26) . Water absorption under both of the relative humidity conditions was higher with higher PVP contents, because it allowed water molecules to easily migrate into the matrix system, which led to increased moisture uptake as well as absorption of water (25) . Hydrophobic DBS containing patches are tough to hydrate, especially at 15 %. It is clear from Table I that the patches remained intact and stable during and aft er water uptake capacity studies.
Fourier Transform Infrared (FTIR) studies
FTIR spectra (Fig. 1a,b ) of individual polymers (Eudragit E 100, RSPO and RLPO) and PVP and TT including a combined mixture of E 100/PVP/TT; RSPO/RLPO/TT were compared for changes in spectral shift s in the mixture. FTIR spectra of the E 100/PVP, RSPO/ RLPO and the drug TT combined mixture are shown in Fig. 1a,b . All peaks of the polymers used in the mixture were observed in the FTIR spectra. FTIR spectra of the drug and combined mixtures revealed the following bands: -OH stretching at 3437.50 cm . Polymer and drug compatibility is of the paramount importance. The FTIR study clearly showed that there were no signifi cant spectral shift s in peaks corresponding to diff erent Eudragit polymers or the drug (19) . There were, however, a few overlaps in characteristic peaks of the drug and the polymer. This confi rms that there were no interactions and indicates the compatibility of the drug with other components.
In vitro release studies
The 8-h cumulative re lease (%) of the matrix patches is shown in Fig. 2 . The fi gure depicts an increase in the release percentage with an increase in matrix patch plasticiser percentage for the DBS containing patches. However, in the case of E 100 based matrix In vitro release studies were conducted to ascertain the drug diff usion patt ern from the matrix patches. The following interesting discussion could be drawn from the observed results. The percentage of release of TT was higher with PVP containing patches, this may be due to the dissolution of hydrophilic PVP in the buff er medium, forming pores on the matrix patch and leaching the drug from the formulation into the solution, thus increasing the rate of diff usion into the patch (19).
It is not only the PVP but also the plasticizer that infl uences the drug release behaviour in the transdermal delivery system from matrix patches. An increase in the number of plasticizer molecules between polymer chains reduces the inter-molecular att ractive forces between the polymer chains, thus leading to easy diff usion out of the matrix patch. According to the report by Siepmann et al. (27) , while DBS is the right plasticizer for fast release, DBP should be selected for more prolonged drug release. The hydrophilic TEC plasticizer tends to absorb moisture and leach it out from the matrix patch, leading to disruption of polymeric chain integrity resulting in pores and reduction of plasticizer content, which increases drug diff usion out of the matrix patch (22) ; in contrast, DBP is hydrophobic and yields the opposite eff ect.
Release kinetics data treatment
As regards release ki netics, the best-fi t was found with Higuchi's model, which calculates mass transport processes using the fi rst-order release kinetics equation. All the nvalues for formulations containing plasticizer TEC exceeded 0.89, which suggests either Case-2 relaxation or super Case-2 transport of polymeric chain erosion (Table II) . The Higuchi model is established on the hypotheses that the initial drug concentration in patches is higher than its solubility in the receptor and that the swelling of matrix patches and dissolution rates are negligible (28) . Results showed that formulations containing plasticizer DBS followed the Higuchi release model. According to the Higuchi model, the DBS formulations followed a diff usion controlled drug release mechanism.
In vitro permeation studies Series C and E were selected for in vitro permeation studies based on the above excellent physicochemical, mechanical and in vitro release characteristics of transdermal patches. As shown in Fig. 3 , formulations C1 and E1 showed the highest cumulative percentage of drug permeation, 63.07 and 63.25 %, respectively. The initial rapid release (burst eff ect) was due to rapid movement of the drug from the surface of the matrix. Aft er the burst effect, the drug was released gradually at a regular pace, achieving a controlled release state. In vitro permeation study exhibited concentration dependent kinetics. Amongst all formulations, the two formulations tested for salivary secretion, the fi rst with E 100 and higher PVP content and the second with the RSPO-RLPO combination with PVP (C1 and E1) showed rapid initial permeation (Fig. 3) , which is desirable for transdermal delivery. Both parameters, the gradient of drug concentration as well as the vehicle-membrane partition coeffi cient were infl uenced by the extent of drug solubility in the vehicle (16, 19) . The permeation percen tage and permeation rate for the selected formulations (C1 and E1) showed higher rapid initial permeation and permeation rate ( , respectively) compared to other formulations. Hence, these two formulations were chosen for further in vivo animal studies. Model  A1  A2  A3  B1  B2  B3  C1  C2 In vivo animal studies
Salivary secretion
Based on the results of mechanical, physicochemical and in vitro release/permeation study, patches C1 and E1 were selected for the in vivo animal study. Whole saliva secreted in the oral cavity in 10 minutes was collected aft er 15 minutes of pilocarpine stimulation. Aft er 1 and 12-hour administration of oral TT, there was a 1.68 and 2.39 fold decrease in whole saliva secretion, respectively, compared to control rats (Fig. 4a,b) . This shows that oral TT markedly suppresses pilocarpine-stimulated salivation. Salivary secretion studies indicated higher activity of oral TT in the salivary gland than the transdermal matrix patch containing TT (10) . A decrease was observed in the total amount of saliva collected in the second hour aft er patch administration, demonstrating that transdermal TT exerted a lesser eff ect on salivary glands than oral administration. The main salivary secretion of transdermal application produced lower suppression of pilocarpine-stimulated salivation. The results showed that the suppression of pilocarpine-stimulated salivation was greatly reduced aft er 12 h of removal of both of the matrix patch formulations. These observations demonstrate the advantages of the TT containing transdermal patch over oral formulation, leading to less dry mouth. In addition, controlled release from transdermal formulations for the muscarinic receptor resulted in longer duration of action, albeit with slower onset (29) . Fig. 5a shows the morphology of a healthy normal urinary bladder consisting of multilayers of transitional cell epithelium, sub-mucosa and muscle layers. Fig. 5b and 5c give the microscopic picture of the group treated with 0.75 % acetic acid. Necrosis of the transitional cells and fl at ulcer atrophy of the mucosa epithelium with the presence of neutrophils and lymphocytes suggest acute infl ammation. This demonstrates that acetic acid has caused damage to the bladder. Fig. 5d provides microscopic information for the group that was treated with acetic acid and received oral TT treatment. It shows near normal urinary bladder with no evidence of infl ammatory cells, which confi rms the positive healing eff ect of oral tolterodine. Fig. 5e and 5f give the microscope picture for groups treated with TT transdermal patches. Focal areas of necrosis and ulceration of the mucosa with mild to moderate infl ammation in sub-mucosa indicates bett er healing process in C1 and slow healing in E1.
Histopathology in t he bladder infl ammation model
While the urinary bladder of the former was normal and intact, the latt er displayed transitional cell necrosis, infl ammatory infi ltration and ulceration of mucosa, indicating acute cystitis. However, the oral TT treated animals had near normal structures in the bladder, indicating complete healing. Histopathology of the urinary bladder of the C1 treated group exhibited fast regeneration of the transitional epithelium while the E1 treated group with a similar bladder structure as C1 displayed mild ulceration in mucosa with scatt ered infl ammation. However, slides from the transdermal matrix patch revealed infl ammation in the bladder with mild to moderate infl ammation in sub-mucosa indicating the beginning of the healing process. Nevertheless, it was slower than oral TT, which may be explained as follows: fi rst, since transdermal patch formulation followed the controlledrelease patt ern, it took time for the drug to reach the target site. Hence, a further 24-hour study is required to evaluate the complete healing eff ect. Second, the drug loading was insuffi cient to produce a signifi cant therapeutic eff ect due to the smaller area available for patch application on rat skin compared to humans. Anyhow, drug loading can be augmented by increasing the drug concentration or patch application area.
CONCLUSIONS
Analysis of our experimental data fi ndings suggest that, amongst the transdermal patches studied, the C1 patch (Eudragit E 100/PVP/DBP) had the most eff ective polymer and plasticizer combination. This polymeric matrix patch, which had the ideal physicochemical and mechanical and in vitro permeation profi les, could be applied directly to the skin for t he OAB therapy. In vivo studies revealed that the C1 patch treated animals not only had higher salivary secretion but also achieved faster epithelial bladder regeneration compared to the E1 formulation. Thus, this study has established the eff ectiveness of transdermal TT matrix patch formulations in treating OAB in addition to reducing the dry mouth eff ects. Results also showed the feasibility of tolterodine tartrate transdermal delivery in OAB treatment. Further work on establishing the effi cacy of therapeutic activity of the drug is to be carried out via pharmacokinetic and pharmacodynamic studies.
